本报讯(记者马薇)9月30日，无锡市医疗健康"产医研融合"创新成果交流会举行，9项医疗卫生惠民便民 创新成果集中发布。 现场，无锡与国家癌症中心签署新一轮深化合作协议，共同深入开展全民癌症防控行动，探索肿瘤早诊 早治模式，通过早筛、早诊、早治无缝衔接，有效减轻社会医疗成本与家庭经济负担。2026年"医惠锡 城"新产品暨"一键e赔"功能上线，推出创新药械纳入保障、增加DRG除外责任等多项服务，进一步减轻 群众就医负担。一批高标准医疗康养设备在基层医疗卫生机构投放启用。据悉，今年，无锡计划向基层 医疗卫生机构投放10台高标准CT设备，向基层公办养老机构投放一批智能康养设备，让群众就医检查 更便利、康复养老更舒心。8家新一代互联网医院正式上线，将为市民提供升级版的"互联网+处方购 药""互联网+复诊""互联网+护理"服务。 会上，无锡市宣布新引进一批医学专家团队和高层次医疗卫生人才，成立药物临床试验机构联盟，并发 布2025年第一批生物医药创新产品目录。无锡市国联健康基金会正式揭牌，首期募集资金3000万元，用 于医学科研、人才培养和困难群体帮扶。同时，8家银行联合发布生物医药专项贷产品，首批为16家企 业提供综合 ...

2025年成为中国创新药发展的标志性年份。 仅在2025年上半年，国家药监局就批准上市创新药43款，其中40款由国内企业自主研发，3款为跨国企 业进口。这一数字背后，是中国创新药产业经过多年布局后迎来的成果爆发期。 国家层面密集出台的支持政策为创新药发展提供了强劲动力。9月1日，国家药监局副局长徐景和在2025 年"全国药品安全宣传周"启动仪式上透露，"十四五"期间，共批准创新药210个、创新医疗（002173） 器械269个，且均保持加速增长态势。 | 发布时间 | 发布单位 | 主要内容 | | --- | --- | --- | | 2025年1月 | 国务院办公厅发 | 通过完善审评审批机制、加强知识产权保护、积 | | | 布《关于全面深 | 极支持创新药推广使用等措施,从制度设计上鼓 | | | 化药品医疗器械 | 励和激发药品创新,为产业发展提供透明、稳定、 | | | 临管改革促进疾 | 可预期的政策环境,并明确通过多种措施努力缩 | | | 药产业高质量发 | 短审评审批时限,进一步加快创新药品上市进 | | | 展的意见》 | 程。 | | 2025年3月 | 《政府工作报 | 要培育生物 ...

9月29日，创新医疗盘中上涨2.09%，截至14:24，报20.50元/股，成交4.36亿元，换手率5.17%，总市值 90.46亿元。 资金流向方面，主力资金净流入948.33万元，特大单买入1413.69万元，占比3.25%，卖出1068.71万元， 占比2.45%；大单买入8593.82万元，占比19.73%，卖出7990.48万元，占比18.34%。 创新医疗今年以来股价涨157.54%，近5个交易日跌4.78%，近20日跌18.62%，近60日涨35.14%。 创新医疗所属申万行业为：医药生物-医疗服务-医院。所属概念板块包括：医疗美容、民营医院、互联 医疗、医疗器械、小盘等。 截至6月30日，创新医疗股东户数8.20万，较上期增加20.38%；人均流通股5074股，较上期减少 16.93%。2025年1月-6月，创新医疗实现营业收入4.02亿元，同比减少1.60%；归母净利润-1136.13万 元，同比增长29.12%。 分红方面，创新医疗A股上市后累计派现5587.29万元。近三年，累计派现0.00元。 责任编辑：小浪快报 今年以来创新医疗已经18次登上龙虎榜，最近一次登上龙虎榜为9月5日，当日 ...

Group 1 - The core focus of the news is the recent institutional research conducted on Innovation Medical Management Co., Ltd., highlighting the advancements and product offerings of its subsidiary, Bole Brain Machine [1][2] - The research event took place on September 25, with participation from eight institutions, including Guohai Securities and Dongwu Securities, showcasing the company's commitment to transparency and engagement with investors [1] - Bole Brain Machine's C-end product, Cyberlink AC5, features user-friendly design and advanced brain-machine interface technology, aimed at improving the quality of life for patients with motor impairments [1][2] Group 2 - Clinical trials for the medical version of Bole Brain Machine's products are progressing well, with over 100 patient tests completed, showing significant improvements in motor function for both new and long-term patients [2] - The C-end product weighs 1.5 kg and includes two batteries with a six-hour lifespan each, designed for daily use and convenience for patients [2] - Future product development includes plans for lower limb rehabilitation products and a focus on invasive technology routes, with ongoing research into intelligent peripheral nerve stimulation systems [2][3] Group 3 - The C-end product is priced based on the value it provides to hemiplegic patients, potentially saving families 40,000 to 60,000 yuan annually in the Jiangsu, Zhejiang, and Shanghai regions [3] - Innovation Medical holds a 68.356% stake in Bole Brain Machine, which is included in the company's consolidated financial statements, indicating a strong financial interest in the subsidiary's success [3]

Group 1: Company Overview and Event Details - The investor relations activity was conducted as a live performance, showcasing the subsidiary Boling Brain Machine's introduction video and product demonstrations [2] - The event took place on September 25, 2025, at the Innovation Medical Hangzhou branch [2] Group 2: Product Features and Clinical Testing - Boling Brain Machine products are designed to be lightweight, user-friendly, and simple to operate, utilizing brain-machine interface technology to enhance patient rehabilitation [3] - Over 100 patients have participated in multi-center clinical tests, showing significant improvements in Fugl-Meyer scores for both newly diagnosed and long-term stroke patients [3][4] Group 3: Product Specifications and Future Developments - The C-end product weighs 1.5 kg and has a battery life of approximately 6 hours per battery, with two batteries included [3] - Future products include a dexterous hand for fine motor control and a pneumatic glove for gross motor actions, with ongoing research into invasive technology [4] Group 4: Economic Impact and Cost Savings - The C-end product can save families between 40,000 to 60,000 CNY annually by reducing the need for full-time caregivers [6] - Traditional rehabilitation costs can reach 65,000 CNY per year, while the Boling Brain Machine allows for home-based training, significantly lowering expenses [6] Group 5: Company Ownership and Market Position - The company holds a 68.356% stake in Boling Brain Machine, which is included in the consolidated financial statements [6]

Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Group 1 - The A-share market saw a significant decline in brain-computer interface concept stocks, with several companies experiencing drops of over 5% [1] - Notable companies that fell over 5% include Dineike, Xiangyu Medical, Meihao Medical, Chengdu Huamei, and Tom Cat [1] - Other companies such as Yanshan Technology, Zhongke Information, Aipeng Medical, Nanjing Panda, Weisi Medical, Innovation Medical, Robot, Mailande, Beiqingsong, Botuo Biological, and Rongtai Health dropped over 4% [1]

Core Viewpoint - The A-share market is experiencing a decline, with the Shanghai Composite Index down by 1.12% and a total trading volume of 1,274.25 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3,785.77 points, reflecting a decrease of 1.12% [1] - The total trading volume in the A-share market is 1,274.25 billion yuan [1] Group 2: Technical Indicators - A total of 236 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA down by 3.16% from 10-day MA [1] - Beautiful Ecology: 5-day MA down by 1.66% from 10-day MA [1] - Jiayun Technology: 5-day MA down by 1.65% from 10-day MA [1] Group 3: Individual Stock Performance - Innovation Medical (002173) is down 6.83% with a latest price of 20.06 yuan, showing a deviation of -13.43% from the 10-day moving average [1] - Beautiful Ecology (000010) is down 7.83% with a latest price of 4.12 yuan, showing a deviation of -11.34% from the 10-day moving average [1] - Jiayun Technology (300242) is down 4.48% with a latest price of 4.05 yuan, showing a deviation of -7.11% from the 10-day moving average [1]

Group 1 - The core viewpoint of the article is the strategic partnership between Meinian Health Group and Beijing Guoping Innovation Medical Technology Co., Ltd. to enhance health management services [1] - The collaboration will focus on areas such as health check-ups, chronic disease rehabilitation, medical care, and health management services for both enterprises and individuals [1]